Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases

Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683

Stefano GentileschiRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Cristiana BarrecaRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Francesca BellisaiRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Giovanni BiasiRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Maria Giuseppina BriziRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Renato De StefanoRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Marta FabbroniRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Antonella FioravantiRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Elena FratiRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Enrico SelviRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Antonio VitaleRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Luca CantariniRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyCorrespondence[email protected]

Bruno FredianiRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Mauro GaleazziRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

show all

References

Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683. doi:10.1517/14712598.2015.1103733.
PubMed Web of Science ®Google Scholar
Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620. doi:10.1136/annrheumdis-2012-203090.
PubMed Web of Science ®Google Scholar
Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612. doi:10.1136/annrheumdis-2012-203091.
PubMed Web of Science ®Google Scholar
Park W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25. doi:10.1186/s13075-016-0930-4.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date